C erviCal total disc replacement (CTDR) is an increasingly accepted option for the treatment of cervical radiculopathy. 25, 35 Several high-quality, prospective randomized controlled trials (RCTs) have demonstrated long-term outcomes of CTDR to be equivalent or superior 5, 6, [11] [12] [13] [14] 19, 28, 29, 31, 33, [40] [41] [42] to those achieved with anterior cervical discectomy and fusion (ACDF). Following arthrodesis, increased mechanical stresses are observed at adjacent levels, 1, 2, 13, 28, 38, 41 potentially leading to adjacentsegment pathology. 7, 16, 18, 22, 24 By preserving motion at the abbreviatioNS ACDF = anterior cervical discectomy and fusion; AE = adverse event; CTDR = cervical total disc replacement; FDA = Food and Drug Administration; ICER = incremental cost-effectiveness ratio; IDE = investigational device exemption; NIS = Nationwide Inpatient Sample; NMB = net monetary benefit; QALYs = qualityadjusted life years; RCT = randomized controlled trial; SF-36 = 36-Item Short Form Health Survey; WTP = willingness to pay. obJective The purpose of this study was to evaluate the 7-year cost-effectiveness of cervical total disc replacement (CTDR) versus anterior cervical discectomy and fusion (ACDF) for the treatment of patients with single-level symptomatic degenerative disc disease. A change in the spending trajectory for spine care is to be achieved, in part, through the selection of interventions that have been proven effective yet cost less than other options. This analysis complements and builds upon findings from other cost-effectiveness evaluations of CTDR through the use of long-term, patient-level data from a randomized study. MethoDS This was a 7-year health economic evaluation comparing CTDR versus ACDF from the US commercial payer perspective. Prospectively collected health care resource utilization and treatment effects (quality-adjusted life years [QALYs]) were obtained from individual patient-level adverse event reports and SF-36 data, respectively, from the randomized, multicenter ProDisc-C total disc replacement investigational device exemption (IDE) study and postapproval study. Statistical distributions for unit costs were derived from a commercial claims database and applied using Monte Carlo simulation. Patient-level costs and effects were modeled via multivariate probabilistic analysis. Confidence intervals for 7-year costs, effects, and net monetary benefit (NMB) were obtained using the nonparametric percentile method from results of 10,000 bootstrap simulations. The robustness of results was assessed through scenario analysis and within a parametric regression model controlling for baseline variables. reSUltS Seven-year follow-up data were available for more than 70% of the 209 randomized patients. In the basecase analysis, CTDR resulted in mean per-patient cost savings of $12,789 (95% CI $5362-$20,856) and per-patient QALY gains of 0.16 (95% CI −0.073 to 0.39) compared with ACDF over 7 years. CTDR was more effective and less costly in 90.8% of probabilistic simulations. CTDR was cost-effective in 99.8% of sensitivity analysis simulations and generated a mean incremental NMB of $20,679 (95% CI $6053-$35,377) per patient at a willingness-to-pay threshold of $50,000/QALY. coNclUSioNS Based on this modeling evaluation, CTDR was found to be more effective and less costly over a 7-year time horizon for patients with single-level symptomatic degenerative disc disease. These results are robust across a range of scenarios and perspectives and are intended to support value-based decision making.
index level, CTDR is intended to reduce the incidence of symptomatic degeneration at adjacent levels. 15, 39, 45 Previous modeling evaluations have demonstrated single-level CTDR to be cost-effective relative to ACDF. A simulation study that used probabilities from the literature and cost data from the Nationwide Inpatient Sample (NIS) found that single-level CTDR became cost-effective after 9.75 years compared with ACDF. 36 A recent study using a subset of ProDisc-C investigational device exemption (IDE) study data and NIS complication data found that CTDR resulted in cost savings of $17,540 ($102,274 vs $119,814) over ACDF at 5 years while providing 0.03 additional quality-adjusted life years (QALYs) (2.84 vs 2.81). Ultimately, CTDR was cost-effective compared with ACDF ($35,976 vs $42,618/QALY). 27, 34 However, these published modeling studies are not based on long-term patient-level medical resource utilization and outcomes as observed in randomized trials.
The purpose of this study was to calculate the 7-year cost-effectiveness of CTDR versus ACDF from a US commercial payer perspective using prospectively collected patient-level outcome and complication data from randomized patients. The results are intended to support value-based treatment decision making.
Methods

Study Design
We conducted a trial-based analysis of the cost utility of CTDR versus ACDF from a US payer perspective. Data from a multicenter IDE RCT and post-approval study of 209 patients who received either single-level ProDisc-C total disc replacement (DePuy Synthes) or single-level ACDF served as the basis of the analysis. 29, 45 Patients entering the trial were symptomatic due to single-level degenerative disc disease not responsive to nonoperative management. 29 Patients were followed for 7 years after randomization.
Differences in costs and QALYs between CTDR and ACDF were estimated, modeled stochastically, and evaluated within scenario analyses. The chosen analytical framework sought to adhere as closely as possible to individual patient-level events observed over the 7-year time horizon.
Medical resource Utilization
The occurrence of events or complications triggering resource utilization was derived from patient-level cervical-related adverse event (AE) data submitted to the US Food and Drug Administration (FDA) for the December 2014 annual report. The AE reports described the nature of the events and provided information about actions taken in response to address the AE. As much resource use information as possible was extracted directly from the AE reports; however, in some cases there was inadequate detail to properly quantify the resource use (e.g., physical therapy was reported, but the number of physical therapy visits was not specified). In these instances, the data were supplemented with blinded estimates from the 2 surgeon authors. The surgeon experts were never aware of patients' treatment allocation (i.e., ACDF or CTDR) when providing supplemental information about the treatment associated with the AE. Medical resources included index surgery (inpatient CTDR or inpatient ACDF), diagnostic radiology (radiographs, CT, MRI), injections (facet, transforaminal, epidural, or trigger point), physical therapy, physician office visits, treatment of dysphagia (swallow studies and methylprednisolone, where documented), and treatment of infection (intravenous antibiotic therapy and/or surgical debridement). A third surgeon expert reconciled any disagreements regarding medical resource use. Pain medications were not included, as drug dosage and duration were not available. Resources consumed for routine nonoperative care (e.g., routine postoperative rehabilitation and radiographs) were excluded from the analysis given the interest in incremental, between-group differences.
All secondary surgical interventions in the cervical spine (index level or adjacent level) were identified within AE records and classified for costing purposes into one of the following categories: anterior cervical fusion, posterior cervical fusion, implant removal only, and "other cervical surgery." The latter category comprises 3 cases involving secondary decompressive surgery without fusion or implant removal. A standard regimen of radiographs and physical therapy was assumed to have been required prior to and after each secondary surgery.
Unit costs
Means and standard deviations for costs for medical resources were obtained from the Truven Marketscan Commercial Claims and Encounters database for services rendered between 2000 and 2014. This database consists of claims for several million individuals in the US who receive employer-sponsored insurance, including fee-forservice, capitated, and partially capitated health plans. Payments made to physicians and facilities were included in all applicable cost categories (Table 1) . Unit costs were updated to $US 2014 (June) using the Medical Care Component of the Consumer Price Index and allocated to each AE. These costs were then discounted from the day of the reported AE to each patient's index-surgery date (ACDF or CTDR) at an annual rate of 3% per recommendations from the US Panel on Cost-Effectiveness in Health and Medicine. 44 
Quality of life
The 36-Item Short Form Health Survey (SF-36) was administered at baseline, 6 weeks, 3 months, 6 months, 12 months, 18 months, 24 months, and annually thereafter through 84 months of follow-up to patients within the ProDisc-C IDE and post-approval study. Item-level scores from SF-36 responses were converted into SF-6D utility scores using the algorithm described by Brazier and colleagues. 8, 9 Cumulative, 7-year QALYs were obtained for each patient using the area-under-the-curve method, and were the basis of incremental QALY differences between CTDR and ACDF patients. Utility values were also discounted 3% annually. 44 
Net Monetary Benefit
Incremental net monetary benefit (NMB) was used to describe the incremental cost-effectiveness of CTDR versus ACDF. NMB-also described as net health benefitis an alternative representation of incremental cost-effectiveness ratios (ICERs), representing a singular, monetary measure of incremental cost-effectiveness. 30 NMB overcomes several limitations inherent to the use of ICERs to describe the results of cost-effectiveness analyses. In particular, ICERs have ratio properties and can take on negative values, aspects of which introduce challenges for statistical analysis and interpretation. 30, 32 NMB is derived by rearranging the ICER calculation into a linear function by converting QALYs into monetary units by assum- ing a fixed willingness-to-pay (WTP) threshold (l), as follows: NMB = (λ × ΔQALYs) -ΔCosts. By definition, health interventions with positive incremental NMB values (i.e., greater than $0) are cost-effective at specified thresholds for the value assigned to an incremental QALY. For our base case in this study, we have selected the commonly applied WTP (l) of $50,000/QALY; thresholds from $10,000/QALY to $100,000/QALY were evaluated within sensitivity analysis.
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Monte carlo Simulation and bootstrap analysis
Using the original trial sample of 209 patients, we applied both Monte Carlo simulation and bootstrap sampling with replacement to generate 10,000 complete data sets of cost and effect (QALY) pairs over 7 years. These methods are well established for quantifying parameter and sampling uncertainty within economic evaluation. 4 Within each simulation, unit costs for all medical resource items were drawn randomly from a gamma distribution using the means and standard deviations presented in Table 1 . Mean values for each cost and effect pair from each bootstrap sample were used to construct nonparametric confidence intervals for costs, QALYs, and NMB using the percentile method. 4 The simulation accounted for missing data within the 7-year time horizon in several ways. Missing SF-6D data occurred due to either missed visits (e.g., lost follow-up or death) or incomplete SF-36 questionnaires (i.e., missing items). A value of zero was assigned to all utility values from the time of death for patients known to have died during follow-up. In all other cases of lost follow-up, the last known SF-36 item scores were carried forward to generate SF-6D utility scores. For patients who had a subset of missing SF-36 items, imputations were performed using an algorithm for drawing random values from a multivariate normal distribution, with correlations among nonmissing SF-36 items as the basis for this distribution. 23 Imputations for death and secondary surgical interventions were also required for patients lost to follow-up. Death rates from US life tables for patients aged 44-45 years were applied to each year of lost follow-up to impute patient deaths. For secondary surgical interventions, a Poisson model was developed based on observed rates of secondary surgeries for patients in each cohort. R version 3.1.1 was used for all simulations.
Scenario analysis
Several scenarios were evaluated using bootstrap sampling to test a range of plausible input parameters and to consider alternate perspectives. Because commercial payer payment rates were used in the base-case analysis, a scenario was tested within which fixed, mean estimates for Medicare payments (physician and facility) were applied to index surgeries and secondary surgical interventions. We also considered a scenario that assumed equivalent rates of secondary surgical interventions for all patients lost to follow-up regardless of treatment group, rather than rates based on those observed separately for patients in each cohort.
Finally, a societal perspective was considered, wherein the human capital approach to valuing work-related productivity losses due to secondary surgical interventions was considered. Hourly compensation of $31.96 (wages and benefits) for civilian workers-as reported by the U.S. Bureau of Labor Statistics for June 2014-was applied to time off work for each secondary surgical intervention. 10 Based on the opinion of our surgeon authors, the mean amount of time away from work after secondary surgery was taken to be 8 weeks (SD 2.5 weeks), with random draws obtained from a normal distribution within Monte Carlo simulation.
NMb regression
Although significant differences in baseline characteristics were not observed between patient groups in the RCT (Table 2) , we sought to test the robustness of our simulation by adjusting for potential imbalances in clinical and demographic variables within a separate parametric model. We constructed an ordinary least-square regression model to predict NMB using data from all patients with nonmissing SF-6D utility values at baseline, 24-month, and 84-month time points. 20, 21 NMB was modeled with treatment group (ACDF vs CTDR) as the main variable with covariates for age, sex, race, and baseline SF-6D utility values. 
results
Overall, 209 patients were randomized and treated: 103 to CTDR and 106 to ACDF. No significant differences in baseline characteristics or demographics were observed between groups (Table 2) . 29 Full 7-year follow-up data were available for more than 70% of the 209 randomized patients. The remaining 30% of patients had partial data. The proportion of follow-up data available for patients overall was 90.9% for CTDR and 84.1% for ACDF (denominator adjusted for patients who died). Over the 7-year time horizon, SF-6D data were available without imputation for 72% of visits for ACDF patients and 80% of visits for CTDR patients. Data on secondary surgical interventions through 84 months of follow-up were available for 74 (70%) of 106 patients in the ACDF cohort versus 81 (79%) of 103 patients in the CTDR cohort. Without imputation and bootstrapping, there were a total of 31 secondary surgeries among 20 patients in the ACDF cohort compared with 8 secondary surgeries among 8 patients in the CTDR cohort over the 7-year follow-up period.
costs
Predicted mean 7-year costs for patients in the CTDR cohort were $29,697 (95% CI $26,137-$33,721) versus $42,486 (95% CI $36,100-$49,790) for patients in the ACDF cohort (Table 3 ). These differences were principally attributable to costs for secondary surgical interventions, which were $2993 (95% CI $1004-$5711) per CTDR patient versus $11,617 (95% CI $6470-$17,942) per ACDF patient. Smaller differences, also favoring CTDR, were evident in physical therapy and diagnostic radiology categories (Table 3) .
effects
Nondiscounted SF-6D utility values were similar for patients in each cohort at baseline through 6 weeks of follow-up (Table 4) . At each time point beyond 6 weeks, they were slightly higher for patients in the CTDR cohort; at Month 84, the mean SF-6D utility value was 0.68 for ACDF patients versus 0.70 for CTDR patients. These differences and cumulative differences in 7-year QALYs between the 2 cohorts were not statistically significant; the mean cumulative, discounted QALYs over the 7-year period were 4.36 (95% CI 4.19-4.53) and 4.52 (95% CI 4.36-4.68) for ACDF and CTDR, respectively (Table 5) .
cost Utility and NMb
CTDR resulted in lower costs and higher QALYs in 90.8% of base-case simulations (Fig. 1 , lower right quadrant). Assuming a WTP threshold of $50,000/QALY, CTDR generated a positive NMB in 99.8% of simulations (Fig. 1) , and generated a mean NMB of $20,679 (95% CI $6053-$35,377). CTDR was cost-effective relative to ACDF at WTP thresholds ranging from $10,000/QALY to $100,000/QALY.
Scenario analysis
In all scenarios, CTDR generated positive NMB relative to CTDR (Table 3) . When Medicare point estimates were used instead of commercial payer costs for all surgical interventions (index and secondary surgical interventions), mean NMB was $14,317 (95% CI $13,426-$15,407). When identical rates of secondary surgical intervention were assumed for all patients lost to follow-up, the mean NMB for CTDR was slightly lower than the base case: $19,740 (95% CI $5049-$34,439). CTDR generated the highest mean NMB value when the estimated costs of lost productivity attributable to secondary surgical interventions were included: $23,015 (95% CI $7691-$38,494). 
NMb regression
Results from the separate NMB regression model that adjusted for treatment group, age, sex, and baseline SF-6D were similar to those from the base-case simulation, with a mean NMB of CTDR of $19,157 (95% CI $2225-$36,089).
Discussion
Significance of Findings
Cervical arthroplasty technology has been available to patients in the US since the inception of FDA IDE studies in 2007. 3 Since then, 7 CTDR devices have been approved by the FDA after completion of Level 1 studies, and several other designs have been evaluated within noncompleted IDE studies.
3 A large volume of prospectively collected information has been accumulated as a result of these efforts, including postapproval surveillance for each device as mandated by the FDA for 7-10 years. Clinical outcomes have been carefully studied, with general findings of equivalent or superior functional outcomes compared with fusion, significantly reduced reoperation rates, and reduced adjacent-level radiographic changes when compared with patients randomized to ACDF. 26 These results have been achieved despite the learning curve implicit in surgeons' adoption of CTDR.
The challenge to payers and providers of health care is to maximize net benefits obtained from health care expenditures. A consistent criticism is that new health care technologies are more expensive than existing alternatives, while their superior (or even equivalent) efficacy is unproven. Comparative effectiveness research is intended to identify cost-effective medical treatments and, in turn, help curb health care spending. This change in spending trajectory is to be achieved, in part, through the selection of interventions that have been proven effective while costing less than other options. Our analysis found single-level CTDR to be more effective and cost saving compared with single-level ACDF in patients with symptomatic degenerative disc disease. CTDR was both less costly and more effective relative to ACDF through 7 years after surgery. In the base case, mean NMB of CTDR was $20,679 (95% CI $6053-$35,377). Further, the NMB of CTDR was positive for all WTP thresholds ranging from $10,000/QALY to $100,000/QALY. These results in favor of CTDR stem primarily from a large reduction in costs due to reduced rates of secondary surgical intervention and a modest increase in QALYs. These results are robust across a range of plausible parameter values within stochastic simulation, across distinct scenarios (e.g., Medicare or commercial payment rates), and after considering an alternate model structure (NMB regression).
Findings From other Published literature
As with clinical data generated through a variety of study designs, the results of economic evaluation based on data obtained from RCTs should be considered in the context of the full body of evidence, including those obtained from real-world settings. The results of this analysis complement and build upon findings from studies with alternative methodologies, thereby enhancing the evidence base. In 2013, Qureshi and colleagues, relying on expert opinion and data pooled from the literature within a decision-tree model, concluded that additional long-term data were re- quired to confirm the cost-effectiveness of CTDR. 36 Warren and colleagues used single-center data from 31 patients enrolled in the ProDisc-C IDE and found ACDF to be more costly but more effective than CTDR at 2 years. 43 Finally, Radcliff et al. conducted a cost-minimization analysis comparing CTDR to ACDF and observed lower per member per month costs and reoperation rates through 36 months for CDTR patients. 37 This study of "real-world" data revealed that Blue Cross and Blue Shield plans incurred 12% lower costs for CTDR relative to ACDF due to lower readmission rates, fewer mechanical complications, lower index-surgery costs, and lower reoperation rates.
Strengths and limitations
Our study has several strengths that address gaps and limitations in the existing literature. We relied upon empirical outcomes data from patients randomized in a multicenter study and followed for 7 years. Previously published investigations used short-term data and/or data from single centers. Longer-term studies published to date have pooled data from multiple, heterogeneous sources, and required critical assumptions around the nature of modeled health states. Unlike state-transition models, which are impaired by the "memory-less" nature of health states, the model structure chosen herein relies on individual patient-specific experience and does not require assumptions around the independence of past and future health states or correlations between costs and effects within given health states. Whereas prior studies report fixed point estimates for Medicare rates or hospital charges for purposes of calculating costs, we instead have included real-world payment amounts for commercial payers, with consideration of the observed variability around all unit-cost point estimates. Finally, our attention to uncertainty around parameter estimates, sampling, and model structure-through the use of Monte Carlo simulation, bootstrap sampling, and net benefit regression, respectively-lends further to the methodological strength of this study.
This study also has some limitations. First, no information was available outside of AE records on nonoperative resource utilization. Thus the dose and duration of chronic pain medications, as well as the duration of other medical interventions not disclosed to researchers during trial visits, could not be reflected herein. Second, unit costs were not directly obtained within the IDE or postapproval studies. However, the incidence of secondary surgical intervention was captured through up to 7 years of follow-up, and these events likely are the most resource intensive components of postsurgical care after CTDR and ACDF. Therefore, the cost differences reflected in this study include the most economically meaningful component of postsurgery costs for the population. Furthermore, the use of national claims data for unit costing, rather than site-specific unit costs, may lend to greater generalizability. The results of this study also rely on outcomes observed within 1 RCT and postapproval study. The RCT and IDE trial were designed to answer primary questions of efficacy/effectiveness/safety, and not comparative cost-effectiveness. The high degree of internal validity from the RCT came at the price of reduced external validity because study populations, protocols, and circumstances may not be relevant to the real world or diverse populations. However, we feel that our approach still has advantages over health economic evaluations that rely on models that piece together information from multiple studies and sources, and it also has advantages over observational data where study designs are very heterogeneous with varying levels of scientific rigor. We have addressed sampling uncertainty through simulation, but we cannot be certain about the generalizability of these results across all patients with symptomatic degenerative disc disease, nor the experience using different arthroplasty devices. Finally, the use of net monetary benefit (NMB) may not be suitable for readers who feel that complex outcomes of health care cannot be reduced to a single monetary measure. The willingness-to-pay (WTP) concept is highly controversial in economic evaluations. Although its use has expanded enormously over the last 20 years, the internal and external validity of tools to measure WTP are still questioned, both theoretically and methodologically.
conclusions
This study adds to the body of health economic knowledge by quantifying the long-term cost-effectiveness of single-level CTDR versus single-level ACDF for patients with symptomatic degenerative disc disease. Using several analytical approaches that consider multiple sources of uncertainty, CTDR was found to be more effective and less costly than ACDF over 7 years. The economic favorability of CTDR over ACDF for well-selected patients was robust across a range of scenarios and perspectives. In the context of prior studies that demonstrated the shortterm cost-effectiveness of CTDR, our results suggest that CTDR may provide a sustained economic advantage over ACDF. These findings are highly relevant for treatment decision making in a climate of greater accountability for long-term population health.
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